Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statement of Operations

v2.4.0.8
Condensed Consolidated Statement of Operations (USD $)
 3 Months Ended 6 Months Ended
Jun. 30, 2014
Jun. 30, 2013
Jun. 30, 2014
Jun. 30, 2013
Revenue:        
Medical devices $ 690,540 $ 389,394 $ 1,217,293 $ 722,313
Engineering services 506,513 594,598 1,041,471 957,928
Total revenue 1,197,053 983,992 2,258,764 1,680,241
Cost of revenue:        
Cost of medical devices 501,425 296,869 831,550 529,432
Cost of engineering services 650,043 384,119 902,146 731,333
Total cost of revenue 1,151,468 680,988 1,733,696 1,260,765
Operating expenses:        
Sales and marketing 1,849,006 1,255,475 3,380,388 2,471,518
Research and development 698,884 789,966 1,467,426 1,711,672
General and administrative 1,808,613 968,663 3,880,056 2,102,117
Total operating expenses 4,356,503 3,014,104 8,727,870 6,285,307
Loss from operations (4,310,918) (2,711,100) (8,202,802) (5,865,831)
Other income (expense):        
Interest expense (3,777) (673,731) (430,380) (1,312,844)
Gain (loss) on warrant liability 60,457,700    (16,979,000)   
Interest income 1,476 1,555 2,876 2,819
Other expense, net (17,499) (16,680) (29,071) (20,854)
Total other income (expense), net 60,437,900 (688,856) (17,435,575) (1,330,879)
Net income (loss) $ 56,126,982 $ (3,399,956) $ (25,638,377) $ (7,196,710)
Basic net income (loss) per share $ 0.72 $ (0.16) $ (0.35) $ (0.34)
Weighted-average shares used in computing basic per share amounts 78,488,087 21,080,414 72,688,073 20,861,127
Diluted net income (loss) per share $ (0.05) $ (0.16) $ (0.35) $ (0.34)
Weighted-average shares used in computing diluted per share amounts 94,772,411 21,080,414 72,688,073 20,861,127